Vorasidenib Expanded Access Program
- Sponsor
- Servier
- Study ID
- NCT05592743
- Status
- Approved For Marketing
Conditions
- Disease Attributes
- Glioma
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Glandular and Epithelial
- Neoplasms, Nerve Tissue
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Pathologic Processes
- Recurrence
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Vorasidenib — DRUGOral therapy
Study Details
This is an expanded access program to provide vorasidenib for treatment of patients 12 years or older with IDH1- or IDH2-mutated glioma.
Key Dates
- Status verified
- Nov 2024
Related Studies
- Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family MembersRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Novel Serum Markers for Monitoring Response to Anti-Cancer TherapyRecruiting · Stanford University · Stanford, California
- Barrett's Esophagus Related Neoplasia (BERN) ProjectRecruiting · Midwest Biomedical Research Foundation · Kansas City, Missouri
- Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid TumorsRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York